Alpha Cognition Announces Positive Interim Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain Injury
Alpha Cognition (ACOG) announced positive interim preclinical data for ALPHA-1062 in treating mild traumatic brain injury (mTBI), specifically focusing on blast trauma injuries relevant to military personnel. The study, conducted in collaboration with the Seattle Institute of Biomedical and Clinical Research and supported by the US Department of Defense, showed promising results in a rodent model.
The interim data revealed that ALPHA-1062 administration following three consecutive days of blast-induced mTBI reduced neuroinflammation markers and neuropathology. High doses demonstrated reduced myeloid cell activation across multiple brain regions and decreased midbrain astrogliosis one month after blast. Final study results, including neuropathology and neurobehavioral data analysis, are expected in Q2/2025.
Alpha Cognition (ACOG) ha annunciato dati preclinici interim positivi per ALPHA-1062 nel trattamento di lesioni cerebrali traumatiche lievi (mTBI), con particolare attenzione alle lesioni da esplosioni rilevanti per il personale militare. Lo studio, condotto in collaborazione con l'Istituto di Ricerca Biomedica e Clinica di Seattle e supportato dal Dipartimento della Difesa degli Stati Uniti, ha mostrato risultati promettenti in un modello di roditori.
I dati interim hanno rivelato che l'amministrazione di ALPHA-1062 dopo tre giorni consecutivi di mTBI indotto da esplosione ha ridotto i marcatori di neuroinfiammazione e la neuropatologia. Dosi elevate hanno dimostrato una riduzione dell'attivazione delle cellule mieloidi in diverse regioni cerebrali e una diminuzione dell'astrogliosi nel mesencefalo un mese dopo l'esplosione. I risultati finali dello studio, compresa l'analisi della neuropatologia e dei dati neurocomportamentali, sono attesi nel secondo trimestre del 2025.
Alpha Cognition (ACOG) anunció datos preclínicos interinos positivos para ALPHA-1062 en el tratamiento de lesiones cerebrales traumáticas leves (mTBI), enfocándose específicamente en lesiones por explosiones relevantes para el personal militar. El estudio, realizado en colaboración con el Instituto de Investigación Biomédica y Clínica de Seattle y apoyado por el Departamento de Defensa de EE. UU., mostró resultados prometedores en un modelo de roedores.
Los datos interinos revelaron que la administración de ALPHA-1062 tras tres días consecutivos de mTBI inducido por explosión redujo los marcadores de neuroinflamación y la neuropatología. Dosis altas demostraron una reducción de la activación de células mieloides en múltiples regiones cerebrales y disminución de la astrogliosis en el mesencéfalo un mes después de la explosión. Se esperan los resultados finales del estudio, incluyendo el análisis de neuropatología y datos neuroconductuales, en el segundo trimestre de 2025.
알파 코그니션 (ACOG)은 군인에게 중요한 폭발성과 관련된 경미한 외상성 뇌손상(mTBI) 치료를 위한 ALPHA-1062의 긍정적인 중간 전임상 데이터를 발표했습니다. 시애틀 생의학 및 임상 연구소와 협력하여 진행된 이 연구는 미국 국방부의 지원을 받아 쥐 모델에서 유망한 결과를 보여주었습니다.
중간 데이터는 세 번의 연속적인 폭발 유도 mTBI 후 ALPHA-1062 투여가 신경염증 지표 및 신경병리학을 감소시켰음을 보여주었습니다. 고용량은 여러 뇌 영역에서 미엘로이드 세포 활성화를 감소시키고, 폭발 후 한 달째 중뇌 아스트로글리오시스를 줄였습니다. 최종 연구 결과는 신경병리학 및 신경행동 데이터 분석을 포함하여 2025년 2분기에 발표될 예정입니다.
Alpha Cognition (ACOG) a annoncé des données précliniques intermédiaires positives pour ALPHA-1062 dans le traitement des lésions cérébrales traumatiques légères (mTBI), en se concentrant spécifiquement sur les blessures causées par des explosions, pertinentes pour le personnel militaire. L'étude, réalisée en collaboration avec l'Institut de recherche biomédicale et clinique de Seattle et soutenue par le Département de la Défense des États-Unis, a montré des résultats prometteurs dans un modèle de rongeurs.
Les données intermédiaires ont révélé que l'administration de ALPHA-1062 après trois jours consécutifs de mTBI induites par explosion a réduit les marqueurs de neuroinflammation et la neuropathologie. Des doses élevées ont montré une réduction de l'activation des cellules myéloïdes dans plusieurs régions du cerveau et une diminution de l'astrogliose du mésencéphale un mois après l'explosion. Les résultats finaux de l'étude, y compris l'analyse de la neuropathologie et des données neurocomportementales, sont attendus au deuxième trimestre 2025.
Alpha Cognition (ACOG) hat positive interim präklinische Daten für ALPHA-1062 zur Behandlung von leichten traumatischen Hirnverletzungen (mTBI) veröffentlicht, wobei insbesondere auf durch Explosionen verursachte Verletzungen abgestellt wurde, die für das Militärpersonal relevant sind. Die Studie wurde in Zusammenarbeit mit dem Seattle Institute of Biomedical and Clinical Research und unterstützt durch das US-Verteidigungsministerium durchgeführt und zeigte vielversprechende Ergebnisse in einem Rattenmodell.
Die interimistischen Daten zeigten, dass die Verabreichung von ALPHA-1062 nach drei aufeinanderfolgenden Tagen mit blastinduzierter mTBI die Marker der Neuroinflammation und Neuropathologie reduzierte. Hohe Dosen führten zu einer reduzierten Aktivierung von Myeloid-Zellen in mehreren Hirnregionen und einer Abnahme der Astrogliosis im Mittelhirn einen Monat nach der Explosion. Die endgültigen Studienergebnisse, einschließlich der Analyse der Neuropathologie und neuroverhaltensbezogener Daten, werden im 2. Quartal 2025 erwartet.
- Demonstrated reduction in neuroinflammation markers and neuropathology after blast trauma
- High-dose ALPHA-1062 showed effectiveness in reducing myeloid cell activation across multiple brain regions
- US Department of Defense support for the research program
- Final study results not available until Q2/2025
- Still in preclinical stage, requiring significant development before potential commercialization
Insights
The interim preclinical data for ALPHA-1062 in treating blast-induced mild traumatic brain injury (mTBI) shows promising neuroprotective effects. The reduction in neuroinflammation markers and neuropathology, particularly decreased myeloid cell activation and midbrain astrogliosis, suggests potential therapeutic benefits for military personnel exposed to blast trauma. However, several critical aspects require attention:
Key considerations include: 1) This is still early-stage preclinical data with final results not expected until Q2/2025, 2) The transition from rodent models to human trials often faces significant challenges and 3) The Department of Defense backing adds credibility but doesn't guarantee clinical success. The military relevance and unmet medical need in blast-induced mTBI present a substantial market opportunity if successful in later-stage trials.
For a small-cap company (
ACI previously documented extensive functional and neuropathological protection, provided by ALPHA-1062 administration, following a single moderate traumatic brain injury. This second pre-clinical study in a rodent model, supported by the US Department of Defense (DOD), is a collaboration with investigators at the Seattle Institute of Biomedical and Clinical Research (affiliated with both the University of
Key findings demonstrated that, ALPHA-1062 administration reduced levels of neuroinflammation markers and neuropathology that occurs after blast trauma. High dose ALPHA-1062 reduced the levels of myeloid cell activation [CD 68] across multiple brain regions one month after blast. High dose ALPHA-1062 also demonstrated the ability to reduce midbrain astrogliosis [GFAP]. Astrogliosis is a process where brain cells called astrocytes become larger, multiply, and change in response to injury or disease in the brain. “These outcomes indicate a protective effect of ALPHA-1062, and demonstrated a reduction of neuropathology. The data provide further support for the continued development of ALPHA-1062 for the treatment of acute mild traumatic brain injury,” said Denis Kay, ACI’s Chief Scientific Officer. Further analysis of neuropathology and neurobehavioral [functional recovery] data is ongoing with the final study report due Q2/2025.
About Alpha Cognition Inc.
Alpha Cognition Inc. is a clinical stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (“mTBI”), for which there are currently no approved treatment options.
ALPHA-1062, is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease, with expected minimal gastrointestinal side effects. ALPHA-1062’s active metabolite is differentiated from donepezil and rivastigmine in that it binds neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia.
An intranasal formulation of ALPHA-1062 has demonstrated potent preservation brain structure and function in a preclinical model of moderate TBI, where enhanced recovery from the brain injury was also seen. The intranasal formulation is currently being evaluated for its ability to provide protection from a military relevant model of repeated mild TBI, in a program sponsored by the US Department of Defense.
Neither Canadian Securities Exchange (the “CSE”) or the OTC Markets Group, accepts responsibility for the adequacy or accuracy of this release.
Forward-looking Statements
This news release includes forward-looking statements within the meaning of applicable securities laws. Except for statements of historical fact, any information contained in this news release may be a forward‐looking statement that reflects the Company’s current views about future events and are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward‐looking statements by the words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “target,” “seek,” “contemplate,” “continue” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward‐looking statements may include statements regarding the TBI out-licensing plan and associated financing, the availability of funding pursuant to financings, the Company’s business strategy, market size, potential growth opportunities, capital requirements, clinical development activities, the timing and results of clinical trials, regulatory submissions, potential regulatory approval and commercialization of the Company’s products. Although the Company believes to have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. The Company cannot assure that the actual results will be consistent with these forward-looking statements. These forward‐looking statements speak only as of the date of this news release and the Company undertakes no obligation to revise or update any forward‐looking statements for any reason, even if new information becomes available in the future.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241211594504/en/
For further information:
Michael McFadden, CEO
Tel: 1-858-344-4375
info@alphacognition.com
https://www.alphacognition.com/
Source: Alpha Cognition Inc.
FAQ
What are the key findings of ACOG's interim preclinical data for ALPHA-1062?
When will ACOG release the final results of the ALPHA-1062 mTBI study?
What is the military relevance of ACOG's ALPHA-1062 study?
Who is collaborating with ACOG on the ALPHA-1062 mTBI study?
